PDCD1 and metabolic dysfunction-associated steatohepatitis: By contrast, other (non-NASH) mouse models of liver cancer (with or without concomitant damage) reacted to PD1 immunotherapy with tumour regression25, suggesting that lack of response to immunotherapy was associated specifically with NASH–HCC (Extended Data Fig. 3g–i).